期刊
INTERNATIONAL IMMUNOLOGY
卷 34, 期 9, 页码 467-474出版社
OXFORD UNIV PRESS
DOI: 10.1093/intimm/dxac020
关键词
deoxycholic acid (DCA); immune checkpoint inhibitor therapy; lipoteichoic acid (LTA); senescence-associated secretory phenotype (SASP)
类别
资金
- Japan Agency for Medical Research and Development [AMED] [JP21gm1010009]
- Japan Society for the Promotion of Science [JSPS] [19H04002, 20K16121]
- Takeda Science Foundation
- Princess Takamatsu Cancer Research Fund [18-25003]
- Yakult Bio-Science Foundation
- Grants-in-Aid for Scientific Research [20K16121, 19H04002] Funding Source: KAKEN
More than 500 species of microbiota in the human intestine coexist with host cells in the liver, including immune cells. This review discusses the impact of gut microbial components and metabolites on liver cells, especially immune cells, and the mechanisms underlying gut microbiota-mediated liver carcinogenesis, as well as cancer prevention.
More than 500 species of microbiota reside in the human intestine and coexist with humans, their host. Gut microbial metabolites and components are absorbed from the intestine and influence cells in the liver, including hepatocytes and stromal cells, such as liver sinusoidal endothelial cells, hepatic stellate cells, Kupffer cells, natural killer (NK) cells, NK T cells and other immune cells. This gut-originated axis to the liver is called the gut-liver axis, which underscores the importance of the link between the gut and the liver. In this review, we discuss the gut microbial components and metabolites that affect cells in the liver, particularly in association with immune cells, and the related responses. We also highlight the mechanisms underlying gut microbiota-mediated liver carcinogenesis and discuss cancer prevention, including the recently clarified modulation of immune checkpoint inhibitor efficacy by the gut microbiota.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据